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Heterogeneity of CYP3A isoforms 
metabolizing erythromycin and cortisol 
The N-demethylation of erythromycin and 6P-hydroxylation of cortisol are both functions of the glu- 
cocorticoid-inducible CYP3A in human liver microsomes. To determine whether 6P-hydroxylation and 
erythromycin N-demethylation are catalyzed by similar or distinct CYP3A isoforms, erythromycin 
N-demethylase activity, as reflected by the recently described 14[C]-erythromycin breath test, was com- 
pared with urinary 6P-hydroxycortisoYcortiso1 ratios, a measure of cortisol 6P-hydroxylase activity, in 
nine patients. Erythromycin N-demethylation varied fourfold and 6P-hydroxycortisoVcortiso1 ratios var- 
ied sevenfold among the subjects; no correlation was found between these activities (3 = 0.065). New 
noninvasive tests of CYP3A strongly suggest cortisol 6P-hydroxylation and erythromycin N-demethyla- 
tion are performed by distinct CYP3A isoforms. (CLIN PHARMACOL THER 1992;51:18-23.) 
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The hepatic cytochromes P450 are a supergene fam- 
ily of microsomal hemoproteins that oxidize lipophilic 
compounds to polar metabolites for excretion into bile 
and urine. Characterizations of the human liver cy- 
tochromes P450 have revealed at least nine distinct 
gene families.' The glucocorticoid-inducible human 
hepatic CYP3A gene family consist of at least four 
closely related h e m ~ ~ r o t e i n s . ~ . ~  The hepatic CYP3A 
superfamily includes family members CYP3A3 (for- 
merly known as HLp), CYP3A4 (hPCN1 or P450NF), 
CYP3A5 (hPCN3), and CYP3A6 (HLp2 or HFLa). 
The isoforms CYP3A3 and CYP3A4 metabolize clini- 
cally important drugs, including erythromycin, nifedi- 
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pine, cyclosporine, midazolam, quinidine, troleando- 
mycin, and c1otrimazole.l Important endogenous 
substrates, such as testosterone and glucocorticoids, 
also undergo CYP3A-catalyzed metabolism to their 
respective 6P-hydroxylated derivatives in humans495 
and rats.''-'* 
The two major human liver CYP3A isoforms, 
CYP3A3 and CYP3A4, are encoded by distinct genes; 
however, these two genes and proteins are so similar 
that these forms cannot be reliably distinguished by 
oligonucleotide hybridization ~ t u d i e s ' ~ " ~  or immuno- 
chemical detection. l5 By use of noninvasive tests of 
human hepatic CYP3A function, we sought to deter- 
mine whether identical or distinct isoforms of the 
CYP3A gene family performed cortisol 6P-hydroxyla- 
tion and erythromycin N-demethylation. These activi- 
ties were examined by ( I )  urinary 6P-hydroxycorti- 
sol/cortisol ratios and (2) the ['4~]-erythromycin 
breath test, respectively. The urinary 6P-hydroxycorti- 
sol/cortisol ratio corrects for changes in glucocorticoid 
production rates and therefore more closely reflects 
rates of hepatic cortisol 6~-hydroxylation.'6.'7 On the 
basis of the observation that erythromycin is a specific 
substrate for the hepatic C Y P ~ A , ~ . ' ~  Watkins et a1.18 
recently showed that measurement of exhaled 14c02 
after administration of ['4~]-erythromycin provides a 
specific and reproducible noninvasive measurement of 
the amounts of the hepatic immunoreactive CYP3A 
and erythromycin N-demethylase activity in liver mi- 
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Table I. Measurement of urinary 66-hydroxycortisol/cortisol ratios and [14c]-erythromycin metabolism at 60 
minutes in subjects with hypertension 
24-Hr urine % Total 14C- 
6P-OH Ratio of erythromycin 
Patient Age Ideal body cortisol urinary 6P-OH metabolism 
No. (yr) Gender Race weight (%) (mglday) cortisollcortisol (60 min) Medications 
1 45 Female Black 110 222.7 8.7 4.0 None 
2 65 Female Black 121 158.1 5.3 3.1 Ibuprofen, glyburide hy - 
drochlorothiazide, 
chlorazepate dipotassium 
3 57 Female White 139 443.5 7.4 2.6 Atenolol, triamterene, 
hydrochlorothiazide, 
calcium 
4 47 Female Black 147 360.0 14.2 2.3 Gemfibrozil, atenolol 
5 52 Female Black 174 222.7 28.6 2.0 Propanolol, hydrochlor- 
othiazide 
6 50 Female White 223 386.4 14.6 1 .O Chlorthalidone 
7 72 Male White 97 219.8 9.6 2.1 P-Blocker study drug 
8 67 Male White 115 363.6 6.6 1.9 P-Blocker study drug 
9 50 Male White 185 198.0 3.9 1.7 Diltiazem, atenolol, aspirin 
crosomes. Moreover, because erythromycin decreases 
the clearance of methylprednisolone in humans,19 
it seemed reasonable to propose that cortisol 6P-hy- 
droxylation and erythromycin N-demethylation may 
be performed by the same or similar CYP3A iso- 
form(s). To examine this possibility, the erythromycin 
N-demethylation activity was measured by the 
[14~]-erythromycin breath test in a convenience sam- 
ple of nine patients with hypertension whose cortisol 
6P-hydroxylase activity was previously characterized. 
Despite the abundant evidence for a common catalyst 
for these reactions, we conclude that erythromycin 
N-demethylation and cortisol 6P-hydroxylation pro- 
ceed by distinct pathways in humans. 
MATERIAL AND METHODS 
[14~]-~-~ethyl-erythromycin and Aquasol scintilla- 
tion cocktail were obtained from Du Pont Diagnostic 
Imaging Division (North Billerica, Mass.). Methyl- 
benzethonium hydroxide and thymolphthalein were 
obtained from Sigma Chemical Co. (St. Louis, Mo.). 
Patient selection. A group of 28 patients (age 
range, 45 to 72 years) recently diagnosed with hyper- 
tension were prospectively enrolled in the study as 
paid volunteers. All patients had diastolic blood pres- 
sures between 90 and 110 mm Hg on at least two sep- 
arate occasions. Patients who exhibited cardiac dis- 
ease, pulmonary disease, or diabetes mellitus were 
excluded from the study. (All patients underwent de- 
termination of plasma renin and aldosterone to ex- 
clude primary hyperaldosteronism or hyperreninemic 
state before inclusion in the study.) Informed consent 
was obtained from each patient in accordance with a 
protocol approved by the Medical College of Virginia 
Committee for the Conduct of Human Research (Rich- 
mond, Va.). Each volunteer had a plasma free cortisol 
determination at 8 AM and a 24-hour urine collection 
for cortisol, 6P-hydroxycortisol, and creatinine deter- 
mination. All antihypertensive medications were dis- 
continued for at least 1 month before plasma and urine 
cortisol and 66-hydroxycortisol collections. After suc- 
cessful completion of these tests, patients received 
antihypertensive medications as deemed appropriate 
by their private physician. The patients were subse- 
quently asked to participate in the [14~]-erythromycin 
breath test protocol. A convenience sample of nine 
of the 28 volunteers consented to participate in the 
['4~]-erythromycin breath test protocol. 
Measurement of urinary 6P-hydroxycortisol. Uri- 
nary free cortisol was measured at Hazelton Labora- 
tory, Vienna, Va., by radioimmunoassay. Urinary 6P- 
hydroxycortisol values were determined by the 
laboratory of P. Saenger by use of a radioimmunoas- 
say.I6 A single patient's urine (patient 9) underwent 
urinary 6P-hydroxycortisol and cortisol profiling by 
HPLC analysis, following the method of Kishida and 
~ukush ima .~ '  
['4~]-~rythromycin breath test protocol. The 
[14~]-~-methyl-erythromycin breath test protocol was 
performed in a manner identical to previously pub- 
lished methods.18 Ideal body weight was determined 
by comparison with charts obtained from the Society 
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Fig. 1. Nine volunteers underwent a 24-hour urine collection for cortisol, 6P-hydroxycortisol, and 
creatinine determination. Urinary free cortisol was measured at Hazelton Laboratory, Vienna Va., 
by radioimmunoassay. Urinary 6P-hydroxycortisol values were determined by the laboratory of P. 
Saenger by radioimmunoassay. l 8  Results were expressed as the ratio of urinary 6P-hydroxycorti- 
sol/cortisol. The ['4C]-N-methyl-erythromycin breath test protocol was performed as described 
p r e v i o u ~ l y . ~ ~  Regression analyses were used to assess the relationship between 6P-hydroxycorti- 
sol/cortisol ratios and ['4C]-erythromycin clearance. 
of Actuaries and Association of Life Insurance Medi- 
cal Directors of America, 1979 Build 
Statistical analyses. Regression analyses were used 
to assess the relationship between 6P-hydroxycorti- 
sol/cortisol ratios and ['4~]-erythromycin clearance 
and to evaluate the effect of the potential confounders 
of age, gender, race, and percentage of ideal body 
weight. Differences between group means were as- 
sessed with the Student t test. 
RESULTS 
Plasma free cortisol (8 AM) was normal in the nine 
patients with newly detected hypertension participat- 
ing in this study (results not shown). From measure- 
ments of 6P-hydroxycortisol and of cortisol in 24-hour 
urine collections obtained in these patients, 6P- 
hydroxylase activity was estimated as the ratio of uri- 
nary 6P-hydroxycortisol and cortisol (6P-hydroxy- 
cortisol/cortisol). As described previously, this ratio 
corrects for changes in glucocorticoid production rates 
and therefore more closely reflects rates of cortisol 
6P-hydro~ylation. '~~'~ The urinary 6P-hydroxycorti- 
sol/cortisol ratios ranged from 3.9 to 28.6 (sevenfold) 
among the patients (Table I). This range is similiar to 
previously measured control values in adults.26 No 
significant association was found between age, gen- 
der, or race and the ratio of urinary 6P-hydroxycorti- 
sol/cortisol . 
The patients then underwent ['4~]-erythromycin 
breath test analyses between 9 and 11 AM (within 2 
hours of breakfast). [ ' 4 ~ ] - ~ ~ t h r o m y c i n  N-demethyla- 
tion curves revealed a fourfold difference in the l4co2 
production among patients. Of the total administered 
dose of ['4~]-~-methyl-erythromycin, 1 .O% to 4.0% 
was detected as l4co, exhaled in the first hour (Table 
I). The amount of ' 4 ~ ~ ,  exhaled after 2 hours was 
2.0% to 4.9% of the total administered dose. This 
range of values is not significantly different from pub- 
lished results of ['4~]-erythromycin breath tests car- 
ried out on subjects without hypertension.'8 The 
[14~]-erythromycin breath test results, expressed as a 
percentage of total dose of ['4~]-~-methyl-erythromy- 
cin metabolized at 60 minutes, and the urinary 6P- 
hydroxycortisol/cortisol ratio showed no statistical as- 
sociation (Fig. 1; r2 = 0.065). 
Of the medications being taken by the participants, 
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Fig. 2. The ['4C]-N-methyl-erythromycin breath test protocol was performed as described previ- 
o u s ~ ~ ~ ~  in nine volunteers. Ideal body weight was determined by comparison with charts obtained 
from the Society of Actuaries and Association of Life Insurance Medical Directors of America, 
1979 Build Study .23 Regression analyses were used to assess the relationship between ['4C]-eryth- 
rornycin N-dernethylation and percentage of ideal body weight, when examined by gender. 
only the diltiazem ingested by patient 9 could poten- 
tially interfere with this study by competitively inhib- 
iting CYP3A and reducing 14c02 p r o d ~ c t i o n . ~ ~  Pa- 
tient 9 displayed the lowest [14~]-erythromycin 
metabolism of the men tested and the lowest urinary 
6P-hydroxycortisol/cortisol ratio. 
No significant gender-dependent difference in eryth- 
romycin N-demethylation was detected in this small 
patient population (p = 0.36). However, it was ob- 
served that percentage of ideal body weight was sig- 
nificantly negatively associated with the metabolism 
of [14~]-~-methyl-erythromycin at 60 minutes in both 
men and women (Fig. 2; 3 = 0.91 in women; r2 = 
0.90 in men). When the effect of percentage of ideal 
body weight was compared with the [14~] -~-methy l -  
erythromycin metabolism at 60 minutes in the group 
as a whole, the correlation was less remarkable (r2 = 
0.46). Even though the single obese male patient was 
also receiving treatment with diltiazam, a calcium 
channel blocker metabolized by C Y P ~ A , ~ ~  exclusion 
of this subject from the analyses still left a negative 
correlation between [14~]-erythromycin N-demethyla- 
tion and percentage of ideal body weight (r2 = 0.42). 
However, when urinary 6P-hydroxycortisol/cortisol 
ratios were compared with percentage of ideal body 
weight, this ratio was not found to show an associa- 
tion (r2 = 0.15). 
DISCUSSION 
The most striking finding was the lack of correla- 
tion ( 3  = 0.065) between our estimates of 6P- 
hydroxylation and of erythromycin N-demethylation in 
each subject, even though these catalytic activities are 
supported by CYP3A-related isoforms in human liver 
micro some^.^^^^'^ This suggests that closely related 
but separate CYP3A isoforms in the liver mediate 
these two activities. Studies of an anhepatic man 
strongly support the conclusion that the [14c]-erythro- 
mycin breath test largely reflects CYP3A4-catalyzed 
erythromycin N-demethylation in the liver.24 How- 
ever, extrahepatic CYP3A-related cytochromes have 
been detected immunohistochemically in human kid- 
ney, small intestine, polymorphonuclear leukocytes, 
pancreas, gall bladder, skin, testes, and ovaries25 and 
could account for a significant amount of urinary ex- 
cretion of 66-hydroxycortisol. 
22 Hunt e t  al. 
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The ['4C]-erythromycin breath test, performed in 
this small group of patients with hypertension exhib- 
ited similiar rates of [14~]-~-methyl-erythromycin me- 
tabolism at 60 and 120 minutes to those obtained for a 
hospitalized population." A fourfold range of values 
was seen in both patient groups. Patients with hyper- 
tension exhibited a range of values (sevenfold varia- 
tion) in urinary 6P-hydroxycortisollcortisol ratios sim- 
ilar to results from patients without hypertension.26 
Preliminary studies had revealed increased hepatic 
cortisol 6P-hydroxylase activity, as reflected by uri- 
nary 6P-hydroxycortisol/cortisol ratios,I6 in a subset 
of patients with essential hypertension, most of whom 
were black (Watlington CO, Wright JT, Grogan WM. 
Unpublished observations, July 1990). However, de- 
spite the suggestion that 6P-hydroxycortisol evokes 
hypertension,27'29 the measured parameters of 6P- 
hydroxycortisol production did not support this hy- 
pothesis within this group of patients with hyperten- 
sion. This may be attributable to the wide variety of 
etiologic factors that contribute to hypertension, in ad- 
dition to 6P-hydroxycortisol, as well as a sampling ar- 
tifact attributable to the small size of our patient pop- 
ulation. 
The [14~]-erythromycin N-demethylation activity 
showed a strong negative association with percentage 
of ideal body weight but no association with 6P- 
hydroxylase activity. This finding suggests the intrigu- 
ing possibility that specific CYP3A isoforms may de- 
crease in obese subjects. It would be desirable to con- 
firm this novel observation with additional techniques 
to exclude such alternative explanations as an expan- 
sion of the body's formaldehyde pool, resulting in a 
lower apparent rates of l4co2 production. Increases in 
total hepatic cytochrome P450 content, as well as the 
ethanol-inducible CYP2E1, have recently been de- 
scribed in a strain of obese rats.30 The possibility that 
obesity resulted in the reciprocal repression of other 
isoforms, a commonly observed effect of induction, 
was not examined. The present approach of using 
noninvasive methods holds promise as a way to eluci- 
date the roles that obesity and other previously unrec- 
ognized factors play in explaining interindividual vari- 
ations in the expression of the human liver 
cytochromes P450. 
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